Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

NCT05029063 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1828

Enrollment

OTHER

Sponsor class

Conditions

Venous Thromboembolism
Cancer

Interventions

DRUG: Rivaroxaban 10 MG

Sponsor

Ottawa Hospital Research Institute